CVS Group Divests Crematoria Business and Expands Footprint in Australia

 

CVS Group plc (LSE:CVSG) has completed the sale of its Crematoria division to Anima Care UK Limited for £42.4 million, a strategic move aimed at refining its business focus. This transaction is expected to generate a one-time profit of £32 million in the company’s financial results for FY2025.

Simultaneously, CVS has broadened its Australian operations through the acquisition of VPP Group PTY Ltd, which adds six veterinary practice locations in Victoria. This acquisition brings CVS’s total presence in Australia to 28 practices spread over 42 sites, strengthening its position in the region.

These strategic initiatives are designed to sharpen CVS’s core service offerings and improve its market competitiveness.

Outlook

CVS Group continues to report healthy revenue growth and benefits from strong corporate developments. However, investors should weigh this against challenges such as margin pressures, relatively high valuation ratios, and some overbought technical indicators, which temper the overall outlook. The company’s balanced position reflects both promising growth prospects and valuation risks.

About CVS Group plc

CVS Group plc is an AIM-listed veterinary services provider operating across the UK and Australia. The group emphasizes delivering high-quality clinical care through its extensive network of approximately 460 veterinary practices, including specialist referral centers and out-of-hours facilities. CVS also manages laboratories and an online retail business. Its workforce numbers around 9,000 employees, including 2,400 veterinarians and 3,300 veterinary nurses.

• Average Daily Trading Volume: 346,131

• Technical Sentiment: Hold

• Market Capitalization: £895.3 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Felipe Erazo

• 

  Lee Wild

• 

  The OMG Team

• 

  IQ Option